Skip to search formSkip to main contentSkip to account menu

GI 147211

Known as: GI-147211, GI147211 
National Institutes of Health

Related topics

Related topics

2 relations
OSI 211

Broader (1)

lurtotecan

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2005
Review
2005
Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of…
PURPOSE Liposomal lurtotecan (OSI-211) is a liposomal formulation of the water-soluble topoisomerase I inhibitor lurtotecan… 
Review
1998
Review
1998
Clinical applications of the camptothecins.
Highly Cited
1998
Highly Cited
1998
Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice
Purpose: We have previously reported that DX-8951f, a water-soluble and nonprodrug camptothecin (CPT) derivative, exhibits both… 
1998
1998
Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks.
GI1147211 is a 7-substituted 10,11-ethylenedioxy-20(S)-camptothecin analogue that inhibits the nuclear enzyme topoisomerase I. In… 
1998
1998
A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion.
GI147211 is a novel, totally synthetic camptothecin with promising preclinical and early clinical activity. This study was… 
Review
1997
Review
1997
Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.
Topoisomerase I inhibitors constitute a new class of anti-cancer agents. Recently, topotecan and irinotecan were registered for… 
Highly Cited
1997
Highly Cited
1997
Simple and versatile high-performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of camptothecin anticancer drugs.
1997
1997
The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor.
Topoisomerase I inhibitors are new compounds of interest for cancer chemotherapy. We performed a study with GI147211, a new… 
1996
1996
Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration.
Topoisomerase I inhibitors are interesting anti-cancer agents with a novel mechanism of action. We performed a phase I study with… 
Highly Cited
1995
Highly Cited
1995
In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues.
The development of camptothecin-like compounds as inhibitors of topoisomerase I for the treatment of resistant tumors has… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License